Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies (original) (raw)
Collins, J. M. Functional imaging in phase I studies: decorations or decision making? J. Clin. Oncol.21, 2807–2809 (2003). PubMed Google Scholar
O'Connor, J. P., Jackson, A., Parker, G. J. & Jayson, G. C. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer96, 189–195 (2007). CASPubMedPubMed Central Google Scholar
Zweifel, M. & Padhani, A. R. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur. J. Nucl. Med. Mol. Imaging37 (Suppl. 1), 164–182 (2010). CAS Google Scholar
Tofts, P. S. et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging10, 223–232 (1999). CASPubMed Google Scholar
Dowlati, A. et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res.62, 3408–3416 (2002). CASPubMed Google Scholar
Galbraith, S. M. et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol.20, 3826–3840 (2002). CASPubMed Google Scholar
Jayson, G. C. et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl Cancer Inst.94, 1484–1493 (2002). CASPubMed Google Scholar
Galbraith, S. M. et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol.21, 2831–2842 (2003). CASPubMed Google Scholar
Leach, M. O. et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br. J. Cancer92, 1599–1610 (2005). CASPubMedPubMed Central Google Scholar
Tofts, P. S. & Kermode, A. G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn. Reson. Med.17, 357–367 (1991). CASPubMed Google Scholar
Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med.9, 669–676 (2003). CASPubMed Google Scholar
Thorpe, P. E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res.10, 415–427 (2004). PubMed Google Scholar
McPhail, L. D., Griffiths, J. R. & Robinson, S. P. Assessment of tumor response to the vascular disrupting agents 5, 6-dimethylxanthenone-4-acetic acid or combretastatin-a4-phosphate by intrinsic susceptibility magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys.69, 1238–1245 (2007). CASPubMed Google Scholar
Koh, D. M. et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur. Radiol.19, 2728–2738 (2009). PubMed Google Scholar
Padhani, A. R. & Miles, K. A. Multiparametric imaging of tumor response to therapy. Radiology256, 348–364 (2010). PubMed Google Scholar
Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95 (2007). CASPubMedPubMed Central Google Scholar
O'Connor, J. P. et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin. Cancer Res.15, 6674–6682 (2009). CASPubMedPubMed Central Google Scholar
Wong, C. I. et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J. Clin. Oncol.27, 4718–4726 (2009). CASPubMed Google Scholar
Dingemans, A. M. et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann. Oncol.22, 559–566 (2011). PubMed Google Scholar
Barboriak, D. P. et al. Treatment of recurrent glioblastoma multiforme with bevacizumab and irinotecan leads to rapid decreases in tumor plasma volume and _K_trans. Presented at the Radiological Society of North America (RSNA) meeting, SST09–05 (Chicago, 2007).
Padhani, A. R. et al. DCE-MRI demonstration of antivascular effects of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to human subjects with advanced solid tumours. In _Proc. 16_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM)16, 773 (Toronto, 2008). Google Scholar
Mitchell, C. L. et al. A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother. Pharmacol.68, 631–641 (2011). CASPubMed Google Scholar
Wedam, S. B. et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol.24, 769–777 (2006). CASPubMed Google Scholar
Gutin, P. H. et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys.75, 156–163 (2009). CASPubMedPubMed Central Google Scholar
Zhang, W. et al. Acute effects of bevacizumab on glioblastoma vascularity assessed with DCE-MRI and relation to patient survival. In _Proc. 17_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM)17, 282 (Honolulu, 2009). Google Scholar
Hahn, O. M. et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J. Clin. Oncol.26, 4572–4578 (2008). CASPubMedPubMed Central Google Scholar
Flaherty, K. T. et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol. Ther.7, 496–501 (2008). CASPubMed Google Scholar
Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol.27, 3027–3035 (2009). CASPubMedPubMed Central Google Scholar
Mross, K. et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin. Cancer Res.16, 311–319 (2010). CASPubMed Google Scholar
Hurwitz, H. I. et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res.15, 4220–4227 (2009). CASPubMed Google Scholar
Spratlin, J. L. et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol.28, 1780–1787 (2010). Google Scholar
de Bono, J. S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature467, 543–549 (2010). CASPubMed Google Scholar
Galbraith, S. M. et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed.15, 132–142 (2002). PubMed Google Scholar
Jackson, A. et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br. J. Radiol.76, 153–162 (2003). CASPubMed Google Scholar
Mross, K. et al. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J. Angiogenes. Res.1, 5 (2009). PubMedPubMed Central Google Scholar
Messiou, C. et al. An exploratory open-label, non-randomised, single centre methodology study to compare dynamic contrast enhanced CT and MRI as markers of changes in vascular activity mediated by a positive control agent (cediranib), a potent inhibitor of VEGF-driven angiogenesis in patients with advanced solid tumours. In _Proc. 19_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM)19, 3143 (Montréal, 2011). Google Scholar
US National Library of Medicine. ClinicalTrials.gov[online],.
Li, S. P. et al. Evaluating the early effects of anti-angiogenic treatment in human breast cancer with intrinsic susceptibility-weighted and diffusion-weighted MRI: initial observations. In _Proc. 19_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM)19, 342 (Montréal, 2011). Google Scholar
Gururangan, S. et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J. Clin. Oncol.28, 3069–3075 (2010). CASPubMedPubMed Central Google Scholar
Kreisl, T. N. et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro. Oncol.13, 1143–1150 (2011). CASPubMedPubMed Central Google Scholar
Siegel, A. B. et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol.26, 2992–2998 (2008). CASPubMed Google Scholar
Lockhart, A. C. et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J. Clin. Oncol.28, 207–214 (2010). CASPubMed Google Scholar
Gollob, J. et al. Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement [abstract]. J. Clin. Oncol.28 (Suppl. 15), a3042 (2010). Google Scholar
Drevs, J. et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.25, 3045–3054 (2007). CASPubMed Google Scholar
Kelly, R. J. et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin. Cancer Res.17, 1190–1199 (2011). CASPubMedPubMed Central Google Scholar
Kloos, R. T. et al. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol.27, 1675–1684 (2009). CASPubMedPubMed Central Google Scholar
Lam, E. T. et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol.28, 2323–2330 (2010). CASPubMedPubMed Central Google Scholar
Rosen, M. A. et al. DCE-MRI demonstrates antivascular properties of sorafenib in metastatic hormone-resistant prostate cancer. In _Proc. 18_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM)18, 4845 (Stockholm, 2010). Google Scholar
Machiels, J. P. et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006–2001. J. Clin. Oncol.28, 21–28 (2010). CASPubMed Google Scholar
Bjarnason, G. A. et al. Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC) [abstract]. J. Clin. Oncol.29 (Suppl.), a4627 (2011). Google Scholar
Desar, I. M. et al. Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T) [abstract]. J. Clin. Oncol.28 (Suppl. 15), a3051 (2010). Google Scholar
Rosen, M. A. et al. Sunitinib induces reductions in tumor vascular permeability and intra-tumor vascular volume in renal cell carcinoma. In _Proc. 19_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM), 19, 3137 (Montréal, 2011). Google Scholar
Murphy, P. S. et al. Vascular response of hepatocellular carcinoma to pazopanib measured by dynamic contrast-enhanced MRI: pharmacokinetic and clinical activity correlations. In _Proc. 18_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM)18, 2720 (Stockholm, 2010). Google Scholar
Iwamoto, F. M. et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06–02). Neuro. Oncol.12, 855–861 (2010). CASPubMedPubMed Central Google Scholar
Stevenson, J. P. et al. Phase I trial of the agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol.21, 4428–4438 (2003). CASPubMed Google Scholar
Akerley, W. L. et al. A randomized phase II trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies [abstract]. J. Clin. Oncol.25 (Suppl. 18), a14060 (2007). Google Scholar
Medved, M. et al. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time. J. Magn. Reson. Imaging20, 122–128 (2004). PubMed Google Scholar
O'Donnell, A. et al. A phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br. J. Cancer93, 876–883 (2005). CASPubMedPubMed Central Google Scholar
Dowlati, A. et al. Novel phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin. Cancer Res.11, 7938–7944 (2005). CASPubMed Google Scholar
Miller, K. D. et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res.11, 3369–3376 (2005). CASPubMed Google Scholar
Annunziata, C. M. et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin. Cancer Res.16, 664–672 (2010). CASPubMedPubMed Central Google Scholar
Conrad, C. et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM) [abstract]. J. Clin. Oncol.22 (Suppl. 14), a1512 (2004). Google Scholar
Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol.21, 3955–3964 (2003). CASPubMed Google Scholar
Mross, K. et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur. J. Cancer41, 1291–1299 (2005). CASPubMed Google Scholar
Thomas, A. L. et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol.23, 4162–4171 (2005). CASPubMed Google Scholar
Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 (PTK/ZK) as second-line mono-therapy in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol.25 (Suppl. 18), a7676 (2007). Google Scholar
Drevs, J. et al. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res.30, 2335–2339 (2010). CASPubMed Google Scholar
Hecht, J. R. et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J. Clin. Oncol.29, 1997–2003 (2011). CASPubMed Google Scholar
Ellis, L. M. Antiangiogenic therapy: more promise and, yet again, more questions. J. Clin. Oncol.21, 3897–3899 (2003). CASPubMed Google Scholar
van Laarhoven, H. W. et al. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organisation for Research and Treatment of Cancer Study 16041). Clin. Cancer Res.16, 1315–1323 (2010). CASPubMed Google Scholar
Liu, G. et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol.23, 5464–5473 (2005). CASPubMed Google Scholar
Jonker, D. J. et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann. Oncol.22, 1413–1419 (2011). CASPubMed Google Scholar
Strumberg, D. et al. Phase I dose escalation study of telatinib (BAY 57–9352) in patients with advanced solid tumours. Br. J. Cancer99, 1579–1585 (2008). CASPubMedPubMed Central Google Scholar
Eskens, F. A. et al. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J. Clin. Oncol.27, 4169–4176 (2009). CASPubMed Google Scholar
Rosen, L. S. et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.25, 2369–2376 (2007). CASPubMed Google Scholar
Michaelis, L. C. & Ratain, M. J. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer6, 409–414 (2006). CASPubMed Google Scholar
Karrison, T. G., Maitland, M. L., Stadler, W. M. & Ratain, M. J. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J. Natl Cancer Inst.99, 1455–1461 (2007). CASPubMed Google Scholar
Ton, N. C. et al. Phase I evaluation of CDP791, a PEGylated Di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin. Cancer Res.13, 7113–7118 (2007). CASPubMed Google Scholar
Jamin, Y. et al. Native T1 is a generic imaging biomarker of response to chemotherapy in neuroblastoma. In Proc. 19_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM), 19, 987 (Montréal,_ 2011). Google Scholar
Roberts, C. et al. The effect of blood inflow and B(1)-field in homogeneity on measurement of the arterial input function in axial 3D spoiled gradient echo dynamic contrast-enhanced MRI. Magn. Reson. Med.65, 108–119 (2011). PubMed Google Scholar
Buckley, D. L. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn. Reson. Med.47, 601–606 (2002). PubMed Google Scholar
Eder, J. P., Jr. et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol.20, 3772–3784 (2002). CASPubMed Google Scholar
McKeage, M. J. et al. 5, 6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin. Cancer Res.12, 1776–1784 (2006). CASPubMed Google Scholar
Sledge, G. W., Jr What is targeted therapy? J. Clin. Oncol.23, 1614–1615 (2005). PubMed Google Scholar
Hayes, C., Padhani, A. R. & Leach, M. O. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed.15, 154–163 (2002). PubMed Google Scholar
Baar, J. et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin. Cancer Res.15, 3583–3590 (2009). CASPubMedPubMed Central Google Scholar
Lankester, K. J. et al. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br. J. Cancer93, 979–985 (2005). CASPubMedPubMed Central Google Scholar
Vriens, D. et al. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. J. Nucl. Med.50, 1777–1784 (2009). CASPubMed Google Scholar
Overmoyer, B. et al. Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin. Cancer Res.13, 5862–5868 (2007). CASPubMed Google Scholar
Akisik, M. F. et al. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology256, 441–449 (2010). PubMed Google Scholar
Hsu, C. Y. et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J. Hepatol.55, 858–865 (2011). CASPubMed Google Scholar
de Lussanet, Q. G. et al. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.63, 1309–1315 (2005). PubMed Google Scholar
Cao, Y. et al. Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int. J. Radiat. Oncol. Biol. Phys.72, 1287–1290 (2008). PubMedPubMed Central Google Scholar
Ceelen, W. et al. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. Int. J. Radiat. Oncol. Biol. Phys.64, 1188–1196 (2006). PubMed Google Scholar
Roe, K. et al. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions. Neoplasia12, 818–825 (2010). PubMedPubMed Central Google Scholar
Benjaminsen, I. C., Melas, E. A., Mathiesen, B. S. & Rofstad, E. K. Limitations of dynamic contrast-enhanced MRI in monitoring radiation-induced changes in the fraction of radiobiologically hypoxic cells in human melanoma xenografts. J. Magn. Reson. Imaging28, 1209–1218 (2008). PubMed Google Scholar
Jackson, A., O'Connor, J. P., Parker, G. J. & Jayson, G. C. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin. Cancer Res.13, 3449–3459 (2007). PubMed Google Scholar
Herbst, R. S. et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet377, 1846–1854 (2011). CASPubMedPubMed Central Google Scholar
Azad, N. S. et al. Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results [abstract]. J. Clin. Oncol.25 (Suppl. 18), a3542 (2007). Google Scholar
Kummar, S. et al. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur. J. Cancer47, 997–1005 (2011). CASPubMedPubMed Central Google Scholar
Posey, J. A. et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res.9, 1323–1332 (2003). CASPubMed Google Scholar
Padhani, A. R. et al. Dynamic MRI evaluation of the triple receptor tyrosine kinase inhibitor BIBF 1120 in patients with advanced solid tumours. In _Proc. 18_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM)14, 765 (Seattle, 2006). Google Scholar
Xiong, H. Q. et al. A phase I study of AEE788, a multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, to determine safety, PK and PD in patients (pts) with advanced colorectal cancer (CRC) and liver metastases [abstract]. J. Clin. Oncol.25 (Suppl. 18), a4065 (2007). Google Scholar
Zweifel, M. et al. Serial R2* MRI to evaluate response to tumour vascular disruptive treatment in a clinical phase I trial. In _Proc. 18_th Annual Scientific Meeting of International Society for Magnetic Resonance in Medicine (ISMRM)18, 2718 (Stockholm, 2010). Google Scholar
Mita, M. M. et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin. Cancer Res.16, 5892–5899 (2010). CASPubMed Google Scholar
Rischin, D. et al. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin. Cancer Res.17, 5152–5160 (2011). CASPubMed Google Scholar
Ricart, A. D. et al. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemother. Pharmacol.68, 959–970 (2011). CASPubMed Google Scholar
Lickliter, J. D. et al. Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. Br. J. Cancer103, 597–606 (2010). CASPubMedPubMed Central Google Scholar
LoRusso, P. M. et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest. New Drugs26, 159–167 (2008). CASPubMed Google Scholar
Gregorc, V. et al. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur. J. Cancer46, 198–206 (2010). CASPubMed Google Scholar
Zucali, P. A. et al. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors [abstract]. J. Clin. Oncol.29 (Suppl. 15), a2522 (2011). Google Scholar